Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loxoprofen prophylaxis for post-implantation syndrome after TEVAR
ChiCTR2500097025Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of loxoprofen in Post-implantation syndrome (PIS) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Incidence of post-implantation syndrome. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
loxoprofen
03
Conditions
Post-implantation syndrome (PIS)
Beyond the preview
Go deeper on ChiCTR2500097025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097025.